Why this challenge?
Lilly’s Clinical Open Innovation initiative believes that open innovation can transform clinical research and development. As we look to engage in the open for insight, innovation, talent, and wisdom to drive new capabilities to fight disease and meet patient needs, we believe there is a large unmet need to devise approaches around the patient’s frame of reference.
The information housed within the first clinical trials registry, which was created by Eli Lilly, is written from a scientist’s point of view and not a patient’s. The same can be said of ClinicalTrials.gov, a registry developed some time later by the U.S. Government. Neither registry does a good job at helping a patient visualize a clinical trial and decide whether it would be a viable option within his or her healthcare journey.
As Lilly is committed to driving patient-centric capabilities, this challenge focuses on the ideas and possibilities for re-imagining clinical trial protocols from a patient’s point of view. To learn more about where clinical trial protocols and ICDs come from, check out this post by the Lilly Clinical Open Innovation Team.
For more information on the Lilly Clinical Open Innovation initiative, please see our website at http://www.lillycoi.com.
Getting Started
Before you begin your redesign, please take a look at the following documents.
Required Sections and Fields document. This document lists all of the required sections and fields that your design must address. Make sure you include them all!
Definitions document. This document explains the type of content that is found in each section of the Required Sections and Fields document, as well as additional fields that you might find in an Informed Consent Document or study protocol that are not required for this challenge. The required sections are marked within the document.
Sample Clinical Trial Documents. For the purpose of consistency, all submitters are required to populate their designs with content from the same study. The sample study deals with advanced non-squamous, non-small cell lung cancer.
Sample Study: A Phase 3, Double-Blind, Placebo-Controlled Study of Maintenance Pemetrexed plus Best Supportive Care versus Best Supportive Care Immediately Following Induction Treatment with Pemetrexed + Cisplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer
This sample study has already been completed. You may pull copy/content from the following resources to use in your design:
More Questions?
For questions about the Clinical Trial Visualization Redesign challenge, email Support@ChallengePost.com.